physician designed vars liposomal glutathione (GSH) The results are in and

540,541 Inclisiran has been approved for treating various cardiovascular conditions, including atherosclerotic cardiovascular disease (ASCVD), primary hypercholesterolemia, mixed dyslipidemia, and heterozygous familial hypercholesterolemia (HeFH)

The neuroprotective effect of caffeine after exposure to neurotoxic compounds has been demonstrated in numerous in-vivo preclinical studies

The reduction in visceral fat, which is strongly associated with insulin resistance, provides additional metabolic benefits

Science 2004

These include targeted action on the central nervous system, excellent bioavailability, and the rapid onset of systemic effects